PDF(Pubmed)
Abstract：
UNASSIGNED: This study aimed to investigate the clinical value of ultrasonography combined with tumor markers in the diagnosis and prediction of recurrence of borderline ovarian tumors (BOTs) and analyze the value of the combination of two different auxiliary examinations in the diagnosis and prediction of recurrence of BOTs.
UNASSIGNED: Here, 221 patients with BOTs confirmed by postoperative pathology were enrolled. Their clinical data, including the ultrasonography features, tumor markers, and clinicopathological data, were retrospectively analyzed.
UNASSIGNED: The statistical data of the 221 cases with BOTs were as follows: 94 (42.5%) with left-sided lesions, 102 (46.2%) with right-sided lesions, and 25 (11.3%) with bilateral lesions. Moreover, 93 cases (42.1%) had a borderline serous tumor, 110 (49.8%) had a borderline mucinous tumor, 12 (5.4%) had a borderline serous mucinous tumor, 2 (0.9%) had a borderline endometrioid tumor, 1 (0.5%) had a borderline Brenner tumor, and 2 (0.9%) had a clear cell BOT. There were 104 cases (47.1%) with a tumor diameter of ≤10 cm and 117 cases (52.9%) with a tumor diameter of >10 cm as suggested by ultrasonography. There were 89 cases (40.3%) with septation, 44 (19.9%) with papilla, and 97 (43.9%) with blood flow as demonstrated by ultrasonography. Carbohydrate antigen 125 (CA 125) was elevated in 132 cases (59.7%), and CA 19-9 was elevated in 52 cases (23.5%).
UNASSIGNED: In general, BOTs are difficult to diagnose preoperatively and have a certain recurrence rate. Ultrasonography combined with CA 125 and CA 19-9 is significant for the preoperative diagnosis and selection of surgical modality for BOTs and could be used as a guideline to achieve good preoperative preparation and avoid secondary surgery.
UNASSIGNED: Here, 221 patients with BOTs confirmed by postoperative pathology were enrolled. Their clinical data, including the ultrasonography features, tumor markers, and clinicopathological data, were retrospectively analyzed.
UNASSIGNED: The statistical data of the 221 cases with BOTs were as follows: 94 (42.5%) with left-sided lesions, 102 (46.2%) with right-sided lesions, and 25 (11.3%) with bilateral lesions. Moreover, 93 cases (42.1%) had a borderline serous tumor, 110 (49.8%) had a borderline mucinous tumor, 12 (5.4%) had a borderline serous mucinous tumor, 2 (0.9%) had a borderline endometrioid tumor, 1 (0.5%) had a borderline Brenner tumor, and 2 (0.9%) had a clear cell BOT. There were 104 cases (47.1%) with a tumor diameter of ≤10 cm and 117 cases (52.9%) with a tumor diameter of >10 cm as suggested by ultrasonography. There were 89 cases (40.3%) with septation, 44 (19.9%) with papilla, and 97 (43.9%) with blood flow as demonstrated by ultrasonography. Carbohydrate antigen 125 (CA 125) was elevated in 132 cases (59.7%), and CA 19-9 was elevated in 52 cases (23.5%).
UNASSIGNED: In general, BOTs are difficult to diagnose preoperatively and have a certain recurrence rate. Ultrasonography combined with CA 125 and CA 19-9 is significant for the preoperative diagnosis and selection of surgical modality for BOTs and could be used as a guideline to achieve good preoperative preparation and avoid secondary surgery.
摘要：
UNASSIGNED:本研究旨在探讨超声检查联合肿瘤标志物在卵巢交界性肿瘤(BOTs)诊断和预测复发中的临床价值,并分析两种不同辅助检查联合应用在诊断和预测BOTs复发中的价值。
未经评估：这里，纳入221例经术后病理证实的BOTs患者。他们的临床数据,包括超声检查的特征,肿瘤标志物,和临床病理数据，进行回顾性分析。
UNASSIGNED：221例BOT患者的统计数据如下：94例（42.5%）左侧病变，102例（46.2%）右侧病变，双侧病变25例（11.3%）。此外，93例(42.1%)有交界性浆液性肿瘤,110例（49.8%）有交界性粘液性肿瘤，12例（5.4％）患有交界性浆液性粘液性肿瘤，2（0.9％）患有交界性子宫内膜样肿瘤，1人（0.5%）患有边缘Brenner肿瘤，2例(0.9%)有透明细胞BOT。超声提示肿瘤直径≤10cm104例（47.1％），肿瘤直径>10cm117例（52.9％）。有89例(40.3%)发生中隔,44（19.9%）有乳头，超声检查显示血流97（43.9％）。糖抗原125（CA125）升高132例（59.7％），CA19-9升高52例(23.5%)。
未经评估：一般来说，BOTs术前诊断困难，有一定的复发率。超声联合CA125和CA19-9对BOT的术前诊断和手术方式的选择具有重要意义，可作为实现良好的术前准备和避免二次手术的指南。
未经评估：这里，纳入221例经术后病理证实的BOTs患者。他们的临床数据,包括超声检查的特征,肿瘤标志物,和临床病理数据，进行回顾性分析。
UNASSIGNED：221例BOT患者的统计数据如下：94例（42.5%）左侧病变，102例（46.2%）右侧病变，双侧病变25例（11.3%）。此外，93例(42.1%)有交界性浆液性肿瘤,110例（49.8%）有交界性粘液性肿瘤，12例（5.4％）患有交界性浆液性粘液性肿瘤，2（0.9％）患有交界性子宫内膜样肿瘤，1人（0.5%）患有边缘Brenner肿瘤，2例(0.9%)有透明细胞BOT。超声提示肿瘤直径≤10cm104例（47.1％），肿瘤直径>10cm117例（52.9％）。有89例(40.3%)发生中隔,44（19.9%）有乳头，超声检查显示血流97（43.9％）。糖抗原125（CA125）升高132例（59.7％），CA19-9升高52例(23.5%)。
未经评估：一般来说，BOTs术前诊断困难，有一定的复发率。超声联合CA125和CA19-9对BOT的术前诊断和手术方式的选择具有重要意义，可作为实现良好的术前准备和避免二次手术的指南。
